Drugs Pharma

Two Indian firms get FDA nod for drugs to treat ulcerative colitis, fight ammonia

HQ Team  November 2, 2022: Two public Indian pharmaceutical companies have received USFDA approvals for selling drugs meant to treat ulcerative colitis and.

Read More
Drugs Pharma

Eli Lilly grants $50 mn for Purdue University research

HQ Team November 2, 2022: Eli Lilly and Company and Purdue University will create a new pharmaceutical manufacturing scholarship program and have renewed.

Read More
Drugs Pharma

Verge Genomics starts human trials with AI drug

Verge Genomics, backed by Eli Lilly and Merck & Co., announced it had dosed a human during clinical trials with a drug discovered.

Read More
Drugs Health

Anti-depressants can rewire brain structure

Anti-depressants can change brain structure and improve mental health.

Read More
Drugs Pharma

EMA cracks the whip on JAK inhibitors for inflammatory disorders

The European Medicines Agency has suggested steps to minimize the risk of severe side effects associated with Janus kinase (JAK) inhibitors, used to.

Read More
Drugs Medical

Liver regeneration possible with new drug, eliminating need for a transplant

New drug can help activate liver regeneration and repair in end-stage liver disease

Read More
Drugs Health

Fast-acting new antidepressant compound found

A new class of antidepressant compound found that hastens the process of improving depression

Read More
Drugs Pharma

Alembic gets USFDA nod for oncology injection Paclitaxel

Alembic Pharmaceuticals, an Indian maker of generic drugs, announced it had received USFDA's final approval for Paclitaxel injection multi-dose vials for use in.

Read More
Drugs Pharma

J&J gets FDA approval for therapy to treat blood cancer

J &J gets approval from FDA for medicine to treat a type of blood cancer-Multiple Myeloma

Read More
Drugs Pharma

Aurobindo to recall two drugs with potential cancer risk

HQ Team October 26, 2022: Aurobindo Pharma US has initiated a voluntary recall of two lots of tablets in the American market due to the.

Read More